Diving shorts:

• Luna Health, a startup that creates an insulin patch pump to help control glucose overnight, collected $ 23.6 million. USD A series funding;
• The company creates a small pump pump with a completely closed cycle insulin dosing algorithm for people with type 1 and 2 diabetes that depend on insulin pens.
• Luna plans to use the funds to improve regulatory applications, to perform clinical trials, to develop production capacity and to expand clinical access programs, the company said in a Monday statement.

Diving insight:

Luna was founded by three executives who have healthcare technology experience and have personal experience to control diabetes – themselves or their children.

CEO John Sjölund and CFO John Brilliant, both founders of the company, used to be Bigfoot Biomedical, a company that is a company that is a company Makes intellectual pen hats For this purpose, regular glucose monitors data are used to provide insulin dose recommendations. Abbott purchased a company 2023

Sean Saint, CEO of Bionics, is also the founder of Luna and a board member.

They started the company to open access to insulin patch pumps for people who perform several daily insulin injections. During the day, people continue to use their insulin pens. However, at night the patch pump can provide a quick -acting insulin by automatically calculating the dose using CGM data.

„We regularly hear from the diabetes community about their battles with night glucose control,” Sjölund Wrote in a blog post on Monday. „Parents of children with type 1 diabetes, who determine several alarms to test blood sugar. Adults with type 2 diabetes who avoid evening activities because they are worried about nightly complications.”

Traditional insulin pumps can help control night glucose control, but they can be complex, expensive and require lifestyle changes. By focusing on night glucose control, Luna can provide a less complex, cheaper device, the company said.

The funding phase was led by Vensana Capital, Minneapolis Venture Capital Fund. Other investors include the Swiss Diabetes Risk Fund, Ascensia Diabetes Care and Winklevoss Capital.